Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today the successful completion of a manufacturing agreement for Lundbeck, an international pharmaceutical company specializing in central nervous system disorders. Scil Proteins was responsible for the process development and early stage GMP manufacturing for a recombinant protein candidate.
"We are delighted that Lundbeck chose our excellent protein manufacturing competence and our first class facilities to deliver their protein" commented Dr. Ulrike Fiedler, CEO of Scil Proteins.
Scil Proteins already manufactures Reteplase, a protein for the treatment of myocardial infarction developed by Boehringer Mannheim and Roche, for the commercial market. The now completed project with Lundbeck builds on Scil Proteins' portfolio of contract development and manufacturing clients. Previous customers have included global and mid-sized pharma companies such as Pfizer, Actavis, Novartis and Dompé as well as numerous biotech companies.
Study highlights the importance of diagnostic tests in pandemic response